Follow
Toni Celià-Terrassa
Toni Celià-Terrassa
Junior group leader at Hospital del Mar Medical Research Institute (IMIM)
Verified email at imim.es
Title
Cited by
Cited by
Year
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization
M Korpal, BJ Ell, FM Buffa, T Ibrahim, MA Blanco, T Celià-Terrassa, ...
Nature medicine 17 (9), 1101-1108, 2011
7082011
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
T Celià-Terrassa, Ó Meca-Cortés, F Mateo, AM De Paz, N Rubio, ...
The Journal of clinical investigation 122 (5), 1849-1868, 2012
4972012
Distinctive properties of metastasis-initiating cells
T Celià-Terrassa, Y Kang
Genes & development 30 (8), 892-908, 2016
3142016
Notch ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche
R Chakrabarti, T Celià-Terrassa, S Kumar, X Hang, Y Wei, A Choudhury, ...
Science 360 (6396), eaan4153, 2018
1742018
Metastatic niche functions and therapeutic opportunities
T Celià-Terrassa, Y Kang
Nature cell biology 20 (8), 868-877, 2018
1532018
Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling
M Shen, YZ Jiang, Y Wei, B Ell, X Sheng, M Esposito, J Kang, X Hang, ...
Cancer cell 35 (1), 64-80. e7, 2019
1492019
Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability
T Celià-Terrassa, C Bastian, DD Liu, B Ell, NM Aiello, Y Wei, J Zamalloa, ...
Nature communications 9 (1), 5005, 2018
1402018
Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis
T Celià-Terrassa, MK Jolly
Cold Spring Harbor perspectives in medicine 10 (7), a036905, 2020
1112020
Dynamics of phenotypic heterogeneity associated with EMT and stemness during cancer progression
MK Jolly, T Celià-Terrassa
Journal of clinical medicine 8 (10), 1542, 2019
1072019
Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis
T Celià-Terrassa, DD Liu, A Choudhury, X Hang, Y Wei, J Zamalloa, ...
Nature cell biology 19 (6), 711-723, 2017
942017
Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program
E Aguilar, I Marin de Mas, E Zodda, S Marin, F Morrish, V Selivanov, ...
Stem cells 34 (5), 1163-1176, 2016
902016
Acid ceramidase as a therapeutic target in metastatic prostate cancer [S]
L Camacho, Ó Meca-Cortés, JL Abad, S García, N Rubio, A Díaz, ...
Journal of lipid research 54 (5), 1207-1220, 2013
802013
SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations
F Mateo, Ó Meca-Cortés, T Celià-Terrassa, Y Fernández, I Abasolo, ...
Molecular cancer 13, 1-17, 2014
772014
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
M von Locquenghien, C Rozalén, T Celià-Terrassa
The Journal of clinical investigation 131 (1), 2021
632021
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy
E Shirvani-Dastgerdi, BY Winer, T Celià-Terrassa, Y Kang, D Tabernero, ...
Journal of hepatology 67 (2), 246-254, 2017
592017
Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1
N Marques, M Sesé, V Cánovas, F Valente, R Bermudo, I De Torres, ...
Oncogene 33 (9), 1124-1134, 2014
372014
OVOL1/2: drivers of epithelial differentiation in development, disease, and reprogramming
K Saxena, S Srikrishnan, T Celia-Terrassa, MK Jolly
Cells Tissues Organs 211 (2), 183-192, 2022
272022
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
I Pérez-Núñez, C Rozalén, JÁ Palomeque, I Sangrador, M Dalmau, ...
Nature cancer 3 (3), 355-370, 2022
252022
Mammary stem cells and breast cancer stem cells: molecular connections and clinical implications
T Celià-Terrassa
Biomedicines 6 (2), 50, 2018
222018
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
EI Rivas, J Linares, M Zwick, A Gómez-Llonin, M Guiu, A Labernadie, ...
Nature Communications 13 (1), 5310, 2022
192022
The system can't perform the operation now. Try again later.
Articles 1–20